AU2010330813B2 - Methods and compositions for treating peripheral vascular disease - Google Patents

Methods and compositions for treating peripheral vascular disease Download PDF

Info

Publication number
AU2010330813B2
AU2010330813B2 AU2010330813A AU2010330813A AU2010330813B2 AU 2010330813 B2 AU2010330813 B2 AU 2010330813B2 AU 2010330813 A AU2010330813 A AU 2010330813A AU 2010330813 A AU2010330813 A AU 2010330813A AU 2010330813 B2 AU2010330813 B2 AU 2010330813B2
Authority
AU
Australia
Prior art keywords
inhibitor
nitric oxide
phosphodiesterase type
oxide donor
arginine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010330813A
Other languages
English (en)
Other versions
AU2010330813A1 (en
AU2010330813A2 (en
Inventor
Crist J. Frangakis
Harry J. Leighton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exodos Life Sciences LP
Original Assignee
Exodos Life Sciences LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exodos Life Sciences LP filed Critical Exodos Life Sciences LP
Publication of AU2010330813A1 publication Critical patent/AU2010330813A1/en
Publication of AU2010330813A2 publication Critical patent/AU2010330813A2/en
Application granted granted Critical
Publication of AU2010330813B2 publication Critical patent/AU2010330813B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2010330813A 2009-12-18 2010-12-17 Methods and compositions for treating peripheral vascular disease Ceased AU2010330813B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28796709P 2009-12-18 2009-12-18
US61/287,967 2009-12-18
PCT/US2010/061054 WO2011075655A1 (en) 2009-12-18 2010-12-17 Methods and compositions for treating peripheral vascular disease

Publications (3)

Publication Number Publication Date
AU2010330813A1 AU2010330813A1 (en) 2012-08-09
AU2010330813A2 AU2010330813A2 (en) 2012-08-09
AU2010330813B2 true AU2010330813B2 (en) 2016-04-28

Family

ID=44167718

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010330813A Ceased AU2010330813B2 (en) 2009-12-18 2010-12-17 Methods and compositions for treating peripheral vascular disease

Country Status (7)

Country Link
US (3) US20130053393A1 (enExample)
EP (1) EP2512479B1 (enExample)
JP (2) JP5960061B2 (enExample)
AU (1) AU2010330813B2 (enExample)
CA (1) CA2784788A1 (enExample)
DK (1) DK2512479T3 (enExample)
WO (1) WO2011075655A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2784826A1 (en) 2009-12-18 2011-06-23 Exodos Life Sciences Limited Partnership Methods and compositions for stable liquid drug formulations
CN103038232B (zh) * 2010-05-26 2016-01-20 阿德弗里奥药品有限责任公司 单独的和与PDE5抑制剂相组合的sGC刺激剂、sGC活化剂用于治疗系统性硬化症(SSc)的用途
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
JP2014526461A (ja) * 2011-09-09 2014-10-06 エスケー ケミカルズ カンパニー，リミテッド Ｐｄｅ５抑制剤を含む皮膚しわ改善用組成物
US10265314B2 (en) 2013-07-25 2019-04-23 Bayer Pharma Aktiengesellschaft SGC stimulators in combination with additional treatment for the therapy of cystic fibrosis
CN104644579A (zh) * 2013-11-25 2015-05-27 天津市汉康医药生物技术有限公司 一种阿伐那非药物组合物
JP6236304B2 (ja) * 2013-12-04 2017-11-22 ライオン株式会社 涙液分泌促進剤
JP6211406B2 (ja) * 2013-12-04 2017-10-11 ライオン株式会社 ムスカリン受容体活性化剤及び唾液分泌促進剤
EP3082428A4 (en) 2013-12-09 2017-08-02 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
AU2015302271B2 (en) 2014-08-12 2019-02-28 Children’s Hospital of Philadelphia Methods of improving myocardial performance in fontan patients using udenafil compositions
EP3226972A4 (en) 2014-12-01 2018-08-08 Achelios Therapeutics, Inc. Methods and compositions for treating migraine and conditions associated with pain
US20180169095A1 (en) * 2015-05-06 2018-06-21 Bayer Pharma Aktiengesellschaft The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of digital ulcers (du) concomitant to systemic sclerosis (ssc)
US9993447B2 (en) * 2015-09-14 2018-06-12 JW Nutritional, LLC Systems and methods for increasing agmatine cellular uptake by oral administration
SG11201802710YA (en) 2015-11-16 2018-06-28 Topadur Pharma Ag 2-phenyl-3,4-dihydropyrrolo[2,1 -f] [1,2,4]triazinone derivatives as phosphodiesterase inhibitors and uses thereof
WO2018167687A1 (en) 2017-03-14 2018-09-20 Atir Holding S.A. Use of heterocyclic compounds in the treatment of pigmented skin
US20200069549A1 (en) 2017-03-14 2020-03-05 Atir Holding S.A. Topical formulation for the treatment of pigmented skin
CA3060525A1 (en) 2017-05-22 2018-11-29 Topadur Pharma Ag Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof
US11117808B2 (en) * 2017-08-01 2021-09-14 University Of Georgia Research Foundation, Inc. Mesoporous nitric oxide-releasing silica particles, methods of making, and uses thereof
KR20190043369A (ko) * 2017-10-18 2019-04-26 주식회사 코아팜바이오 유데나필의 신규한 반고형 제제
MX2017016930A (es) * 2017-12-19 2019-06-20 Malesil Research & Tech Llc Uso del maleato de sildenafil en el tratamiento de ulceras de pie diabetico.
HUE072422T2 (hu) 2018-06-01 2025-11-28 Tavanta Therapeutics Inc Topikális amlodipin sók anorektális betegségesek kezelésére
EP3833395A1 (en) * 2018-08-06 2021-06-16 Nicox S.A. Nitric oxide releasing phosphodiesterase type 5 inhibitor
EP3887376A1 (en) 2018-11-28 2021-10-06 Topadur Pharma AG Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof
WO2020123312A1 (en) 2018-12-09 2020-06-18 Weinberg Assa Method to prevent and treat macular degeneration by vasodilators
AU2020356193A1 (en) 2019-09-24 2022-05-19 Children's Hospital Of Philadelphia Methods of improving exercise performance, single ventricular performance, and myocardial performance index (MPI) in single ventricle heart disease, using udenafil compositions
WO2021245192A1 (en) 2020-06-04 2021-12-09 Topadur Pharma Ag Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof
AU2021388141A1 (en) * 2020-11-25 2023-06-22 Aisa Pharma, Inc. Treatment of raynaud's disease
US11185513B1 (en) * 2021-05-07 2021-11-30 King Abdulaziz University Transfersome-containing transdermal film formulations and methods of use
KR20240064630A (ko) 2021-09-29 2024-05-13 토파두르 파마 아게 2-페닐-3,4-디히드로피롤로[2,l-f][1,2,4]트리아지논 유도체의 국소 조성물 및 이들의 용도
IL314241A (en) 2022-03-02 2024-09-01 Topadur Pharma Ag Topical compositions and uses therof
KR20230129639A (ko) 2022-03-02 2023-09-11 연세대학교 산학협력단 이중작용 pde5 억제제/질산유기에스터의 국소 혈류 증진을 위한 경피 투약 형태

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020182162A1 (en) * 2002-08-07 2002-12-05 Mohsen Shahinpoor Nitric oxide (NO) donor+cGMP-PDE5 inhibitor as a topical drug for enhanced hair growth
US20040110843A1 (en) * 2000-01-10 2004-06-10 Nexmed (Holdings), Inc. Methods of treatment of male erectile dysfunction
US20090053283A1 (en) * 2004-03-01 2009-02-26 Rothbard Jonathan B Compositions And Methods For Treating Diseases
WO2010062366A1 (en) * 2008-10-31 2010-06-03 Arginetix, Inc. Compositions and methods of treating endothelial disorders

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7914814B2 (en) * 1997-09-17 2011-03-29 Strategic Science & Technologies, Llc Topical delivery of arginine of cause beneficial effects
WO2000035434A2 (en) * 1998-12-14 2000-06-22 Cellegy Pharmaceuticals, Inc. Compositions and methods for the treatment of anorectal disorders
US20030105108A1 (en) * 2002-12-19 2003-06-05 Wood Ralph E. Method of treating peripheral vascular diseases, peripheral neuropathies, and autonomic neuropathies
US7737147B2 (en) * 2000-07-27 2010-06-15 Thomas Nadackal Thomas Methods and compositions to enhance the efficacy of phosphodiesterase inhibitors
US6538033B2 (en) 2000-08-29 2003-03-25 Huntington Medical Research Institutes Nitric oxide donor compounds
US7956219B2 (en) * 2002-05-09 2011-06-07 Baker IDI Heart and Diabetes Amino acid analogues
US20020168424A1 (en) * 2002-07-31 2002-11-14 Dr. Mohsen Shahinpoor Nitric oxide (NO) donor+cGMP-PDE5 inhibitor as a topical drug for glaucoma
HUP0401422A2 (en) * 2004-07-15 2006-04-28 G Laszlo Meszaros Use of l-arginine as vasoaktive ingredient absorbing through skin for external application
CA2611856C (en) * 2005-06-29 2018-02-27 Mars, Incorporated Inducing peripheral blood vessel vasodilation using polyphenols provided as cocoa

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040110843A1 (en) * 2000-01-10 2004-06-10 Nexmed (Holdings), Inc. Methods of treatment of male erectile dysfunction
US20020182162A1 (en) * 2002-08-07 2002-12-05 Mohsen Shahinpoor Nitric oxide (NO) donor+cGMP-PDE5 inhibitor as a topical drug for enhanced hair growth
US20090053283A1 (en) * 2004-03-01 2009-02-26 Rothbard Jonathan B Compositions And Methods For Treating Diseases
WO2010062366A1 (en) * 2008-10-31 2010-06-03 Arginetix, Inc. Compositions and methods of treating endothelial disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FRIES, R. et al., "Sildenafil in the Treatment of Raynaud's Phenomenon Resistant to Vasodilatory Therapy in Circulation, 2005, Vol 112, pages 2980-2985 *

Also Published As

Publication number Publication date
US20180036314A1 (en) 2018-02-08
US20150031704A1 (en) 2015-01-29
JP2016166178A (ja) 2016-09-15
US20130053393A1 (en) 2013-02-28
CA2784788A1 (en) 2011-06-23
WO2011075655A1 (en) 2011-06-23
JP2013514995A (ja) 2013-05-02
DK2512479T3 (en) 2016-06-06
AU2010330813A1 (en) 2012-08-09
EP2512479A1 (en) 2012-10-24
JP5960061B2 (ja) 2016-08-02
EP2512479B1 (en) 2016-03-30
EP2512479A4 (en) 2013-07-17
HK1169941A1 (zh) 2013-02-15
AU2010330813A2 (en) 2012-08-09

Similar Documents

Publication Publication Date Title
EP2512479B1 (en) Compositions for treating peripheral vascular disease
CA2323839C (en) Treatment of neuropathy
JP2025060754A (ja) 腎臓疾患または障害を処置するためのビフェニルスルホンアミド化合物
OA12899A (en) Synergistic combination of an alphan-2-delta ligand and a PDEV inhibitor for use in the treatment ofpain.
BRPI0620234A2 (pt) combinação farmacêutica para o tratamento de luts que compreende um inibidor da pde5 e um antagonista muscarìnico
JP2024133735A (ja) Ｉｖ型コラーゲン疾患の処置のためのビフェニルスルホンアミド化合物
CA2660939A1 (en) Pharmaceutical compositions for the treatment of fungal infections
JP2010533650A (ja) 代謝性障害の治療のための組成物
WO2005042022A2 (en) Combination of an activator of solubleguanylate cyclase and an angiotensin ii receptor antagonist
HK1169941B (en) Compositions for treating peripheral vascular disease
WO2005011727A1 (en) Combination of an activator of soluble guanylate cyclase and an ace-inhibitor for the treatment of a cardiovascular or metabolic disorder
US20050148585A1 (en) Treatment of wounds
AU2009302285A1 (en) Combination therapy comprising angiotensin receptor blockers and vasopressin receptor antagonists
KR20030097778A (ko) 상처 치료방법
US20050059660A1 (en) Novel combination
Hong et al. Effects of commercial antiglaucoma drugs to glutamate-induced [Ca2+] i increase in cultured neuroblastoma cells
KR20250052365A (ko) Flt3-억제제를 포함한 암 병용 요법
AU2002301821B2 (en) Treatment of Neuropathy
JP2003146907A (ja) アンジオテンシンｉｉ受容体拮抗剤を含有する医薬組成物
AU2011221426A1 (en) Pharmaceutical compositions for the treatment of fungal infections
KR20080113099A (ko) 근육내 항바이러스 치료

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 16 JUL 2012

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired